Coordination Pharmaceuticals is a drug development company focused on addressing unmet medical needs and improving patient care. Utilizing the NCP platform pioneered by Professor Wenbin Lin at the University of Chicago, the company develops versatile technology that synergizes with existing therapies. Their products are particularly effective in combination with checkpoint blockade inhibitors, enhancing T cell infiltration into lowly immunogenic tumors.
Coordination Pharmaceuticals has made significant strides in the pharmaceutical industry by leveraging its innovative NCP platform. The company's work has the potential to transform patient outcomes, particularly in oncology, by improving the efficacy of current treatments. The affiliation with Professor Wenbin Lin and the University of Chicago underscores the scientific rigor and innovation driving their mission.
